GPCR drug development has led toimportant cardiovascular therapies, such as antagonists of β-adrenergicand angiotensin II receptors for heart failure and hypertension, and agonists ofthe glucagon-like peptide-1 receptor for reducing adverse cardiovascular eventsand other emerging indications. Here, GLP1R is linked to hypertensive disorder.